Literature DB >> 32447991

Ribophorin II is upregulated in myelodysplastic syndromes and prevents apoptosis and cell cycle progression.

Jinhai Ren1, Ying Wang1, Lihua Wang1, Xiaoling Guo1, Xiaonan Guo1.   

Abstract

IMPACT STATEMENT: This study explored the role of ribophorin II (RPN2) in myelodysplastic syndromes (MDSs) cell proliferation and growth and revealed that RPN2 knockdown suppressed OCI-AML3 cell growth and proliferation and triggered cell cycle arrest and elicited apoptosis in OCI-AML3 cells. In addition, it shed light on the etiology of RPN2's role in MDS cell proliferation that RPN2 can negatively impact enhancer of zeste homolog-2 (EZH2) expression, which in turn is able to modulate the cell cycle location and death in OCI-AML3 cells. Hence, RPN2 expression could be a latent predictor of prognosis in patients with MDS.

Entities:  

Keywords:  Myelodysplastic syndrome; apoptosis; cell cycle; enhancer of zeste homolog-2; ribophorin II

Mesh:

Substances:

Year:  2020        PMID: 32447991      PMCID: PMC7357142          DOI: 10.1177/1535370220927996

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  18 in total

1.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.

Authors:  J E Parker; G J Mufti; F Rasool; A Mijovic; S Devereux; A Pagliuca
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.

Authors:  H Makishima; A M Jankowska; R V Tiu; H Szpurka; Y Sugimoto; Z Hu; Y Saunthararajah; K Guinta; M A Keddache; P Putnam; M A Sekeres; A R Moliterno; A F List; M A McDevitt; J P Maciejewski
Journal:  Leukemia       Date:  2010-08-19       Impact factor: 11.528

3.  Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.

Authors:  Feng Xu; Xiao Li; Lingyun Wu; Qingxia Zhang; Rui Yang; Yujuan Yang; Zheng Zhang; Qi He; Chunkang Chang
Journal:  Ann Hematol       Date:  2010-12-02       Impact factor: 3.673

4.  Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.

Authors:  Shigeki Nakagawa; Hirohisa Okabe; Yasuo Sakamoto; Hiromitsu Hayashi; Daisuke Hashimoto; Naomi Yokoyama; Keita Sakamoto; Hideyuki Kuroki; Kosuke Mima; Hidetoshi Nitta; Katsunori Imai; Akira Chikamoto; Masayuki Watanabe; Toru Beppu; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2013-07-26       Impact factor: 5.344

5.  EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation.

Authors:  Roland Hubaux; Kelsie L Thu; Bradley P Coe; Calum MacAulay; Stephen Lam; Wan L Lam
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

Review 6.  An evolving view of the eukaryotic oligosaccharyltransferase.

Authors:  Daniel J Kelleher; Reid Gilmore
Journal:  Glycobiology       Date:  2005-11-29       Impact factor: 4.313

Review 7.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

8.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.

Authors:  A Raza; S Gezer; S Mundle; X Z Gao; S Alvi; R Borok; S Rifkin; A Iftikhar; V Shetty; A Parcharidou
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

9.  Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.

Authors:  Kunju Sridhar; Douglas T Ross; Robert Tibshirani; Atul J Butte; Peter L Greenberg
Journal:  Blood       Date:  2009-10-02       Impact factor: 22.113

10.  A novel platform to enable inhaled naked RNAi medicine for lung cancer.

Authors:  Yu Fujita; Fumitaka Takeshita; Takayuki Mizutani; Tadaaki Ohgi; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Sci Rep       Date:  2013-11-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.